Health services research (text messages, smart pill bottle) for Acute Myeloid Leukemia
This trial tests a mobile intervention to help AML patients take their oral anti-cancer meds correctly. It may help doctors design better educational material to improve adherence.
- Acute Myeloid Leukemia
2 Primary · 4 Secondary · Reporting Duration: At baseline, 1, and 2 months
1 Treatment Group
Health services research (text messages, smart pill bottle)
1 of 1
30 Total Participants · 1 Treatment Group
Primary Treatment: Health services research (text messages, smart pill bottle) · No Placebo Group · N/A
Who is running the clinical trial?
Age 18+ · All Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What purposes does this clinical trial seek to fulfill?
"The primary endpoint examined in this clinical trial, to be evaluated at 2 months, is the response rate of patients with acute myeloid leukemia/myelodysplastic syndrome (AML/MDS) based on their MD Anderson Symptom Inventory score. Secondary metrics include complete remission (CR), partial remissions (PR), and morphologic leukemia-free state (MLFS). All outcomes will be analyzed using univariable logistic regression models that focus on a predictor of daily OAM medication adherence." - Anonymous Online Contributor
What is the current number of participants in this trial?
"Affirmative. Clinicaltrials.gov displays that this clinical trial, initially posted on August 15th 2022 is currently recruiting patients. 30 individuals are needed between two different medical centres for the study's completion." - Anonymous Online Contributor
Are participants currently being enrolled in this clinical experiment?
"As corroborated by clinicaltrials.gov, this study is still recruiting patients as of October 25th 2022. It was initially made available to the public on August 15th 2022." - Anonymous Online Contributor